Invivyd (IVVD) Projected to Post Earnings on Thursday

Invivyd (NASDAQ:IVVD) will likely be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Invivyd to post earnings of ($0.25) per share and revenue of $13.57 million for the quarter.

Invivyd Price Performance

Invivyd stock opened at $0.72 on Thursday. The stock has a market cap of $86.12 million, a P/E ratio of -0.37 and a beta of 0.09. Invivyd has a 1 year low of $0.35 and a 1 year high of $4.74. The firm’s 50 day moving average price is $0.97 and its 200-day moving average price is $0.87.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on IVVD. Morgan Stanley reduced their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. D. Boral Capital reissued a “buy” rating and issued a $9.00 target price on shares of Invivyd in a report on Wednesday, March 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Invivyd in a report on Monday, February 24th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $7.89.

Insider Activity at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 83,817 shares of Invivyd stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $0.54, for a total transaction of $45,261.18. Following the completion of the transaction, the director now directly owns 3,340,520 shares of the company’s stock, valued at $1,803,880.80. The trade was a 2.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 365,943 shares of company stock valued at $171,220. 17.90% of the stock is owned by corporate insiders.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.